MetLife Investment Management’s Acceleron Pharma XLRN Stock Holding History

MetLife Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19,395	Closed	-$1.74M	–	2383
2020 Q1	$1.74M	Hold	19,395	–	–	0.02%	664
2019 Q4	$1.03M	Hold	19,395	–	–	0.01%	1089
2019 Q3	$766K	Sell	19,395 -2,252	-10%	-$97.7K	0.01%	1186
2019 Q2	$889K	Buy	21,647 +2,339	+12%	+$96.8K	0.01%	1164
2019 Q1	$899K	Buy	19,308 +1,902	+11%	+$83.5K	0.01%	1124
2018 Q4	$758K	Hold	17,406	–	–	0.01%	1136
2018 Q3	$996K	Hold	17,406	–	–	0.01%	1122
2018 Q2	$845K	Hold	17,406	–	–	0.01%	1101
2018 Q1	$681K	Hold	17,406	–	–	0.01%	1192
2017 Q4	$739K	Buy	+17,406	New	+$653K	0.01%	1174

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MetLife Investment Management's XLRN Position: Q2 2020 in Review

MetLife Investment Management sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 19,395 shares — an estimated $1.74M sold.

MetLife Investment Management first reported a position in XLRN in Q4 2017 and held it in 10 quarters. The position peaked at $1.74M in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

MetLife Investment Management reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
MetLife Investment Management sold 19,395 Acceleron Pharma shares in Q2 2020, an estimated $1.74M.
MetLife Investment Management first reported a position in Acceleron Pharma in Q4 2017 and held it in 10 quarters.
MetLife Investment Management's Acceleron Pharma position peaked at $1.74M in Q1 2020.
242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.